A Real-World Study of JT001 for COVID-19

Shanghai Vinnerna Biosciences

Status: Active, not recruiting

Conditions: COVID-19

Treatments: Drug: JT001

Study type: Observational

Funder types: Industry

Identifiers

NCT06142201

JT001-PMS-CO02-COVID-19

Details and patient eligibility

About

Real-world disease outcomes and safety in patients with mild to moderate COVID-19 treated with JT001

Enrollment: 7,656 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥18 years old.
2. The novel coronavirus infection (COVID-19) meets at least one of the following five criteria:

1. Diagnosis of novel coronavirus infection; 2) Diagnosed with novel coronavirus pneumonia; 3) The novel coronavirus nucleic acid test is positive; 4) Test positive for novel coronavirus antigen; 5) Culture positive for novel coronavirus.

3. Patients who have not developed severe COVID-19 or died within 28 days of COVID-19 diagnosis, or who have developed severe COVID-19 or died within 28 days of COVID-19 diagnosis, were treated with deuterimodivir hydrobromide tablets or were not treated with anti-novel coronavirus before disease progression.

Exclusion criteria

· Patients who have not developed severe COVID-19 or died within 28 days of COVID-19 diagnosis, or those who have developed severe COVID-19 or died within 28 days of COVID-19 diagnosis, received the following anti-novel coronavirus treatments before disease progression, including: Nematavir tablet/Ritonavir tablet, Azvudine tablet, Monoravir capsule, Zenotavir tablet/Ritonavir tablet, Leritvir tablet, Ambavirzumab/Romisivir injection, human immunoglobulin for COVID-19 or convalescent plasma for COVID-19 survivors.

Trial design

7,656 participants in 2 patient groups

JT001

Treatment:

Drug: JT001

No anti-SARS-CoV-2 treatment

Treatment:

Drug: JT001